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Abstract
Introduction:	Fragile	X	syndrome	(FXS)	is	a	common	monogenetic	cause	of	intellec-
tual	disability,	autism	spectrum	features,	and	a	broad	range	of	other	psychiatric	and	
medical	problems.	FXS	is	caused	by	the	lack	of	the	fragile	X	mental	retardation	pro-
tein	(FMRP),	a	translational	regulator	of	specific	mRNAs	at	the	postsynaptic	compart-
ment.	The	absence	of	FMRP	leads	to	aberrant	synaptic	plasticity,	which	is	believed	to	
be caused by an imbalance in excitatory and inhibitory network functioning of the 
synapse.	Evidence	from	studies	in	mice	demonstrates	that	GABA,	the	major	inhibi-
tory	neurotransmitter	in	the	brain,	and	its	receptors,	is	involved	in	the	pathogenesis	
of	FXS.	Moreover,	several	FXS	phenotypes,	including	social	behavior	deficits,	could	
be corrected in Fmr1	KO	mice	after	acute	treatment	with	GABAB agonists.
Methods:	As	FXS	would	probably	require	a	lifelong	treatment,	we	investigated	the	
effect	of	chronic	treatment	with	the	GABAB agonist baclofen on social behavior in 
Fmr1 KO mice on two behavioral paradigms for social behavior: the automated tube 
test and the three- chamber sociability test.
Results:	Unexpectedly,	chronic	baclofen	treatment	resulted	in	worsening	of	the	FXS	
phenotypes	in	these	behavior	tests.	Strikingly,	baclofen	treatment	also	affected	wild-	
type	animals	 in	both	behavioral	 tests,	 inducing	a	phenotype	 similar	 to	 that	of	un-
treated Fmr1 KO mice.
Conclusion:	Altogether,	the	disappointing	results	of	recent	clinical	trials	with	the	R-	
baclofen enantiomer arbaclofen and our current results indicate that baclofen should 
be reconsidered and further evaluated before its application in targeted treatment 
for	FXS.
K E Y W O R D S
γ-aminobutyric	acid,	baclofen,	FMR1,	fragile	X	mental	retardation	protein,	fragile	X	syndrome,	
targeted treatment
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1  | INTRODUC TION
Fragile	X	syndrome	(FXS)	is	a	major	X-	linked	cause	of	intellectual	dis-
ability	(ID)	and	autism	spectrum	disorders	(ASD).	Features	include	de-
velopmental	delay,	deficits	in	executive	functioning,	and	a	wide	range	
of	 psychiatric	 problems	 such	 as	 repetitive	 behavior,	 social	 deficits,	
hyperactivity,	 anxiety,	 and	 irritability	 (Garber,	 Visootsak,	 &	Warren,	
2008;	 Hersh	 &	 Saul,	 2011;	 Lozano,	 Rosero,	 &	 Hagerman,	 2014).	 In	
addition,	 FXS	 can	 be	 accompanied	 by	 medical	 problems,	 including	
epilepsy,	hyperlaxity,	and	cardiac	disorders	 (Garber	et	al.,	2008;	Kidd	
et	al.,	 2014).	 Currently,	 there	 is	 no	 disease-	modifying	 therapy	 avail-
able. The most common genetic cause of the disease is a CGG repeat 
expansion	 in	the	5′untranslated	region	of	the	FMR1	gene	on	Xq27.3,	
leading	 to	hypermethylation	of	 the	promoter	 region	and	subsequent	
silencing	of	the	gene	(Bell	et	al.,	1991;	Oberle	et	al.,	1991;	Verkerk	et	al.,	
1991). Silencing of transcription of the FMR1 gene results in the ab-
sence	of	 its	protein	product,	the	fragile	X	mental	retardation	protein	
(FMRP).	 FMRP	 is	 an	 RNA-	binding	 protein	 that	 binds	 approximately	
4%	of	the	total	brain’s	mRNA.	Many	of	these	mRNAs	are	coding	for	
proteins	important	in	neuronal	connectivity	and	synaptic	plasticity,	in-
cluding	PSD95,	SAPAP1-	3,	α-	CaMKII,	Arc/Ar3.1,	and	Shank1	(Brown	
et	al.,	2001;	Darnell	et	al.,	2011;	Schutt,	Falley,	Richter,	Kreienkamp,	&	
Kindler,	2009).	FMRP	plays	a	significant	role	in	transporting	these	spe-
cific	mRNAs	to	 the	postsynaptic	compartment	and	subsequent	 local	
translational	control	(Willemsen,	Levenga,	&	Oostra,	2011).	The	Fmr1 
knockout	(KO)	mouse	model	displays	many	phenotypes	similar	to	FXS	
patients,	including	ASD-	like	behaviors	(social	behavioral	deficits,	repet-
itive	behavior),	hyperactivity,	anxiety,	and	audiogenic	seizures,	although	
many of these phenotypes vary depending on the genetic background 
of	the	mouse,	the	age	of	the	mice,	and	among	research	groups	(Mineur,	
Sluyter,	de	Wit,	Oostra,	&	Crusio,	2002;	Moy	et	al.,	2009;	Pietropaolo,	
Guilleminot,	Martin,	D’Amato,	&	Crusio,	2011;	Spencer	et	al.,	2011).
As	many	FXS	patients	manifest	 social	behavior	deficits,	 sleeping	
disorders,	anxiety,	and	seizures,	 involvement	of	 the	brain’s	major	 in-
hibitory γ-	aminobutyric	 acid	 (GABA)	 pathway	 has	 been	 proposed	
(D’Hulst	&	Kooy,	2007).	Both	the	ionotropic	GABAA and the metabo-
tropic	GABAB	receptors	have	been	implicated	in	FXS	and	ASD.	Studies	
have	demonstrated	decreased	expression	of	several	GABAA receptor 
subunits	and	proteins	 involved	 in	the	metabolism	of	the	GABA	neu-
rotransmitter	 (Adusei,	 Pacey,	 Chen,	 &	 Hampson,	 2010;	 D’Hulst	 &	
Kooy,	2007;	Pacey,	Heximer,	&	Hampson,	2009;	Paluszkiewicz,	Martin,	
&	Huntsman,	2011).	The	GABAB receptor acts postsynaptically by hy-
perpolarization	 of	 neurons.	 Presynaptically,	 GABAB receptor activa-
tion	leads	to	reduced	glutamate	release,	resulting	in	reduced	mGluR5	
receptor activation and downstream protein synthesis (reviewed in 
Paluszkiewicz	et	al.,	2011).	The	combination	of	hyperactive	glutama-
tergic	 signaling	and	 the	decrease	of	GABAergic	 signaling	might	 lead	
to	overall	hyperexcitability	in	FXS,	due	to	an	imbalanced	excitatory–
inhibitory	network	function	(Gibson,	Bartley,	Hays,	&	Huber,	2008).
Several	studies	have	now	attempted	to	improve	FXS-	related	symp-
toms	 by	 correcting	 this	 reduced	 GABAergic	 activity,	 using	 baclofen,	
R-	baclofen,	or	arbaclofen.	Baclofen	is	a	structural	analog	of	GABA,	act-
ing	as	agonist	of	the	GABAB receptor. It consists of the potent R- and 
the	less	potent	S-	enantiomer,	 in	equal	amounts	(Sanchez-	Ponce	et	al.,	
2012;	Silverman	et	al.,	2015).	Arbaclofen	(STX209)	is	the	more	effective	
R-	enantiomer	of	baclofen	(Lal	et	al.,	2009).	Acute	arbaclofen	treatment	
corrected several Fmr1	KO	phenotypes,	including	biochemical,	electro-
physiological,	morphological,	and	behavioral	features	(Henderson	et	al.,	
2012).	Acute	R-	baclofen	injection	showed	improvement	in	social	deficits	
in a version of the three- chamber sociability test and hyperactivity (Qin 
et	al.,	 2015).	 In	 addition,	 acute	 baclofen	 treatment	 improved	 sensory	
hypersensitivity,	 electrophysiology,	 social	 behavior,	 and	 hyperactivity	
measures	(Sinclair	et	al.,	2017).	The	above-	mentioned	results	prompted	
the	 initiation	of	a	 randomized	double-	blind	placebo-	controlled	clinical	
trial	with	 arbaclofen	 in	 63	 children	 and	 adults	with	 FXS,	 resulting	 in	
some improvement in post hoc analysis of the most severely affected 
patients (n	=	27)	 (Berry-	Kravis	 et	al.,	 2012).	However,	 the	 subsequent	
larger phase 3 clinical trial with arbaclofen has been terminated prema-
turely,	due	to	lack	of	efficacy	(Berry-	Kravis	et	al.,	2017).
The	assumed	involvement	of	GABAB in social behavior and the 
fact	that	chronic	treatment	might	be	necessary	 in	the	case	of	FXS	
prompted us to evaluate chronic baclofen treatment in two social be-
havioral paradigms: the automated tube test and the three- chamber 
sociability	test.	Unexpectedly,	both	tests	show	a	paradoxical	effect	
of chronic baclofen treatment on social behavior in Fmr1	KO	mice,	
worsening	their	phenotype.	Altogether,	the	latest	results	of	the	clin-
ical	trial	and	our	current	results	indicate	that	baclofen	might	be	ques-
tionable	as	targeted	treatment	for	FXS.
2  | MATERIAL S AND METHODS
2.1 | Animals
Fmr1	KO	mice	 (Mientjes	et	al.,	 2006)	 and	 their	WT	 littermates	were	
bred	in	house	on	a	C57BL/6	background,	using	hemizygous	or	homozy-
gous Fmr1 KO females and WT males for breeding. Only males were 
used,	because	of	the	X-	linked	nature	of	FXS	and	because	females	are	
known to have a different phenotype in the automated tube test (van 
den	Berg,	Lamballais,	&	Kushner,	2015).	Animals	used	in	the	automated	
tube	test	were	housed	individually	after	weaning,	3–4	weeks	postpar-
tum,	as	housing	is	known	to	influence	the	mice	behavior	(de	Esch	et	al.,	
2015).	 For	 the	 three-	chamber	 sociability	 test,	 animals	 were	 group-	
housed	with	3–4	males	per	cage,	with	a	mixed	genotype.	Stranger	mice,	
which	are	used	in	the	three-	chamber	sociability	test,	were	male	age-	
matched	adult	animals	of	a	C57BL/6JRj	background	(Elevage	Janvier,	
Le	Genest-	Saint-	Isle,	 France).	 The	 age	 of	 test	 animals	 during	 experi-
ment	was	between	12	and	16	weeks,	when	mice	reached	young	adult-
hood.	The	mice	were	weighed,	and	mice	that	 lost	more	than	10%	of	
their weight were excluded. Genotyping was performed on toe- clip at 
1 week of age and repeated for validation of the genotype on toe or ear 
tissue	obtained	after	 the	behavioral	experiments.	Animals	were	kept	
under standard laboratory conditions with food and water ad libitum 
and	12-	hr	 light–dark	cycles.	Experiments	were	performed	during	the	
light	phase	at	a	fixed	timeslot.	All	experiments	were	approved	by	the	
local animal welfare committee. The institutional and national guide for 
the care and use of laboratory animals was followed.
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2.2 | Behavioral tests
2.2.1 | Automated tube test
The	 automated	 tube	 test,	 adapted	 from	 the	 original	 tube	 test	
(Lindzey,	 Winston,	 &	 Manosevitz,	 1961),	 has	 been	 developed	 to	
measure	hierarchy	and	social	dominance	and	is	often	used	in	ASD	re-
search	(van	den	Berg	et	al.,	2015).	We	used	the	automated	tube	test	
apparatus	from	Benedictus	b.v.,	a	tube	made	of	transparent	Plexiglas	
with a starting box on each side. The protocol has been described 
earlier	(de	Esch	et	al.,	2015).	In	short,	the	experiment	is	preceded	by	
5 days of training and 2 days of rest. The experimenter was blinded 
for	genotype	and	treatment.	Mice	were	identified	using	a	color	code	
on	the	tail.	Mice	were	placed	in	one	of	the	side	boxes	(starting	box)	
and were motivated to walk to the other side (end box). On the first 
day,	 they	had	to	 reach	the	end	box	within	180	s	and	the	next	day	
within	30	s.	On	day	2	to	4,	the	training	was	repeated	for	three	times	
on	each	side.	If	mice	did	not	leave	the	starting	box	within	5	s,	a	nega-
tive	stimulus,	an	air	puff,	was	administered,	until	 the	tube	was	en-
tered.	After	the	training	week,	the	tournament	week	started.	Each	
day	started	with	two	training	trials,	 followed	by	matches	between	
all	mice	from	both	groups.	During	each	match,	the	designated	mice	
were	placed	in	the	starting	boxes,	one	on	each	side,	and	the	doors	
were opened. The center door opened when both mice were in its 
proximity.	This	was	followed	by	social	interaction,	and	the	match	ter-
minated	when	one	of	the	mice	walked	backward,	entering	its	start-
ing box. The mouse that entered its starting box with all four paws 
was	designated	as	the	loser,	while	the	other	mouse	was	the	winner.	
The	group	that	won	most	matches	was	designated	as	dominant.	All	
matches	were	repeated	on	day	2–4	of	the	tournament	week	in	a	dif-
ferent order and a reversed starting side.
2.2.2 | Three- chamber sociability test
The three- chamber sociability test has been developed to measure 
social interaction and interest for an unfamiliar mouse compared to 
an object (empty cage) and is often used in research on neuropsychi-
atric	diseases	 like	ASD	(Nadler	et	al.,	2004;	Naert,	Callaerts-	Vegh,	&	
D’Hooge,	2011).	The	protocol	is	a	modified	version	of	previous	pub-
lications that have made use of the three- chamber setup (Gantois 
et	al.,	2013;	Nadler	et	al.,	2004).	The	setup	consists	of	a	three-	chamber	
transparent	Plexiglas	cage,	divided	in	a	center,	left	and	right	chambers.	
The left and right chambers contain a wired cylindrical cage where a 
mouse	previously	unknown	to	the	test	mouse,	the	stranger	mouse,	can	
be	placed.	The	setup	contains	 two	cameras,	connected	to	the	ANY-	
maze™	Video	Tracking	System	software	(Stoelting	Co.,	IL,	USA).	Prior	
to	 the	 experiment,	 animals	were	 handled	 for	 2	weeks,	 to	 accustom	
them	to	the	experimenter	and	the	room.	On	the	day	of	the	experiment,	
animals	were	acclimated	to	the	room	for	30	min.	Just	before	the	test,	
each	mouse	was	habituated	to	the	center	chamber	for	5	min,	followed	
by 5 min of the sociability test with a stranger mouse placed in the 
wired	cage	in	the	left	or	right	chamber.	In	the	other	chamber,	an	empty	
cage	was	placed.	The	doors	were	opened,	and	the	mouse	could	explore	
all three chambers. The side where the stranger mouse is placed was 
evenly	distributed	between	genotypes,	 treatments,	and	time	of	day.	
The movements of the mice were recorded and tracked automatically. 
Time	 in	 direct	 contact	with	 the	 stranger	mouse	or	 the	 empty	 cage,	
that	is,	time	spent	sniffing,	was	manually	scored	by	the	experimenter.	
Whenever the nose was pointed to the cage and within a predefined 
circle	around	the	cage,	this	was	considered	sniffing.	The	experimenter	
was blinded for genotype and treatment throughout the experiment.
2.3 | Locomotor activity
Locomotor	 activity	 was	 automatically	 measured	 using	 the	 ANY-	
maze™	Video	Tracking	System	software	during	 the	 three-	chamber	
sociability test.
2.4 | Drug treatment
Mice	were	treated	with	baclofen	(Bufa/Spruyt-	Hillen	B.V.)	in	their	drink-
ing	water.	Aspartame	was	added	to	reduce	the	bitter	taste	in	a	concen-
tration	of	0.1%.	Control	water	contained	aspartame	only.	Drinking	water	
was refreshed three times a week. It has been previously shown that 
baclofen	 crosses	 the	 blood–brain	 barrier	 (van	Bree,	Heijligers-	Feijen,	
de	Boer,	Danhof,	&	Breimer,	1991)	and	that	0.5	mg/ml	of	arbaclofen,	
the	R-	baclofen	enantiomer,	reaches	acceptable	pharmacokinetics	and	
treatment effects in Fmr1	KO	mice	(Henderson	et	al.,	2012).	Racemic	
baclofen consists of both the pharmacologically active R- and the in-
active	 S-	enantiomer,	 in	 equal	 amounts	 (Sanchez-	Ponce	 et	al.,	 2012;	
Silverman	et	al.,	2015).	For	that	reason,	a	dose	of	1	mg/ml	baclofen	was	
used.	Based	on	the	increased	locomotor	activity	that	was	measured	in	
this	dose	of	baclofen,	we	later	reduced	the	dose	to	0.25	mg/ml.	Fmr1 
KO mice and WT littermates were treated with baclofen or aspartame 
drinking water from weaning until the end of the experiment.
2.5 | Statistical analysis
For	the	automated	tube	test,	the	outcome	of	each	match	per	mouse	
was designated as winning or losing. The total number of wins per 
group was summed up and presented as the percentage of matches 
won	from	the	total	amount	of	matches	of	that	day.	A	binomial	distri-
bution test was used to determine a significant difference between 
the total match outcome and the null hypothesis: If both groups are 
similar,	around	half	of	matches	are	won	by	each	group.	To	analyze	
the	 intrinsic	validity	of	 the	test,	 the	percentage	of	matches	with	a	
similar	outcome	to	the	previous	day	(i.e.,	the	stability	of	the	test	out-
come)	was	calculated	(data	not	shown).	A	stability	>70%	compared	to	
the previous day was considered stable.
The	three-	chamber	sociability	 test	data	were	analyzed	with	statis-
tical	 software	 (SPSS	for	Windows,	 IBM,	NY,	USA,	version	24).	Overall	
effects	were	evaluated	with	repeated-	measures	analysis	of	variance	(RM	
ANOVA).	Genotype	(Fmr1 KO and WT littermates) and treatment (ba-
clofen with aspartame and aspartame only) were included as between- 
subject factor. Stranger side (empty and stranger) was included as 
within-	subject	factor,	allowing	for	correction	of	time	spent	sniffing	the	
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stranger cage for the time spent sniffing the empty cage. Data are pre-
sented	as	mean	±	standard	error	(SE).	For	the	locomotion	analysis,	differ-
ences between concentrations were calculated with a two- sided t- test 
and	overall	difference	was	calculated	with	univariate	ANOVA.
3  | RESULTS
3.1 | Chronic baclofen treatment (1 mg/ml) worsens 
the social behavior phenotype in Fmr1 KO mice and 
induces aberrant social behavior in WT littermates
3.1.1 | Automated tube test
As	a	start,	we	performed	a	control	experiment	to	determine	whether	
aspartame	 in	 the	 drinking	water	 affects	 the	 outcome	 of	 the	 ATT.	
These experiments show that Fmr1 KO mice receiving control as-
partame water win most of the matches over their WT littermates 
receiving control aspartame water (Figure 1). This is indicated as a 
dominant phenotype and is similar to the phenotype described for 
Fmr1	KO	mice	with	normal	drinking	water	(de	Esch	et	al.,	2015).
To test whether baclofen treatment affects the dominant 
Fmr1	 KO	 automated	 tube	 test	 phenotype,	we	 treated	 Fmr1 KO 
mice with 1 mg/ml baclofen and compared them to WT litter-
mates	 receiving	 aspartame	 drinking	 water	 only.	 Each	 experi-
ment	 contained	 two	 groups	 of	 six	 mice,	 resulting	 in	 a	 total	 of	
36 matches per day. We show that Fmr1 KO mice treated with 
1 mg/ml baclofen win most matches from WT littermates receiv-
ing	aspartame	water	(Figure	2a),	supporting	no	correction	of	the	
phenotype.	 In	 the	 case	 of	 a	 full	 correction,	 both	 groups	would	
win	 around	50%	of	matches.	 In	 addition,	Fmr1 KO mice treated 
with baclofen became dominant over Fmr1 KO mice receiving 
aspartame	 drinking	water	 (Figure	2b),	 in	 line	with	worsening	 of	
the dominant phenotype. The control experiment of WT litter-
mates receiving aspartame drinking water versus WT littermates 
treated with baclofen shows that WT mice treated with baclofen 
(1	mg/ml)	become	dominant,	implying	an	induced	dominant	phe-
notype (Figure 2c).
3.1.2 | Three- chamber sociability test
The time a mouse spent in direct contact with and sniffing the 
cage	where	 the	 stranger	mouse	was	 placed,	 or	 the	 empty	 cage,	
was manually recorded by the experimenter and is depicted in 
Figure 2d. This measure is expressed as sniffing time and is an 
indication	 for	 sociability	 (Moy	 et	al.,	 2009;	 Nadler	 et	al.,	 2004).	
All	groups	sniffed	the	stranger	mouse	significantly	more	than	the	
empty cage. Fmr1 KO mice receiving aspartame drinking water 
show	an	 increased	sociability	phenotype,	 that	 is,	sniff	 the	stran-
ger mouse more than WT littermates receiving aspartame drink-
ing	water,	when	corrected	for	total	amount	of	sniffing.	WT	mice	
treated with baclofen showed increased time sniffing of the stran-
ger mouse compared to WT mice receiving aspartame water. This 
increased sniffing time was similar to average time sniffing of Fmr1 
KO mice receiving aspartame water. The average time sniffing the 
F IGURE  1 Control experiment of matches between Fmr1 KO 
mice	and	WT	littermates	using	aspartame	drinking	water,	in	the	
automated tube test. Fmr1 KO mice receiving aspartame drinking 
water win most of the matches from WT littermates receiving 
aspartame drinking water (p	=	.054	on	day	1	to	.003	on	day	4,	n	=	4	
mice per group). p values: ^<.05,	*<.01,	**<.001
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F IGURE  2 The effect of 1 mg/ml baclofen treatment on the behavior of Fmr1 KO mice and wild- type littermates in the automated tube 
test	and	the	three-	chamber	sociability	test.	(a–c)	Results	of	the	automated	tube	test,	expressed	in	percentage	of	matches	won.	(a)	Fmr1 KO 
mice	treated	with	baclofen	win	most	matches	against	WT	littermates	receiving	aspartame	drinking	water,	winning	80%	of	the	matches	on	
day	1,	which	increases	to	over	90%	on	day	4	(binomial	test,	p	=	.000,	n = 6 per group). (b) Fmr1 KO mice treated with 1 mg/ml baclofen water 
win most matches against Fmr1	KO	mice	receiving	aspartame	water,	winning	more	than	80%	of	the	matches	(p	=	.000,	n = 6 per group). (c) 
WT	littermates	treated	with	1	mg/ml	baclofen	win	most	matches	against	WT	littermates	receiving	aspartame	water,	winning	more	than	
90%	of	the	matches	(p	=	.000,	n	=	6	per	group).	(d)	Sociability	behavior,	in	the	three-	chamber	sociability	test,	expressed	as	average	time	
spent	sniffing	the	stranger	mouse,	compared	to	the	time	spent	sniffing	the	empty	cage.	All	groups	sniff	the	stranger	mouse	more	than	the	
empty	cage	(two-	way	RM	ANOVA	with	within-	subject	factor	side	of	stranger,	p = .000). Fmr1 KO mice receiving aspartame water sniff the 
stranger	mouse	significantly	more	than	WT	littermates	receiving	aspartame	water	(two-	way	RM	ANOVA	with	stranger	side	as	within-	subject	
factor	and	genotype	as	between-	subject	factor,	p < .003). WT littermates receiving baclofen water sniff the stranger mouse more than WT 
littermates receiving aspartame water (p	=	.008),	making	baclofen-	treated	WT	littermates	comparable	to	Fmr1 KO mice receiving aspartame 
or baclofen. The average time sniffing the stranger was similar for Fmr1	KO	mice	with	and	without	baclofen	treatment	(RM	ANOVA	stranger	
side	*	treatment,	p	=	.869).	Data	are	expressed	as	mean	±	SE;	WT	aspartame	n	=	13,	Fmr1 KO aspartame n	=	13,	WT	baclofen	n	=	11,	Fmr1 
KO baclofen n	=	12.	(e)	Locomotor	activity	during	sociability	phase	of	the	three-	chamber	sociability	test.	WT	and	Fmr1 KO receiving baclofen 
drinking water show increased locomotor activity compared to WT and Fmr1 KO mice receiving aspartame water (two- sided independent- 
samples t-	test,	p = .001 and p	=	.034,	respectively).	Data	presented	as	mean	±	SE.	p-	Values:	^<.05,	*<.01,	**<.001
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stranger was similar for Fmr1 KO mice with and without baclofen 
treatment.
3.2 | Chronic baclofen treatment (1 mg/ml) 
increases locomotor activity
The	question	addressed	 in	 this	paper	was	whether	baclofen	can	
reduce abnormal social behavior of Fmr1	KO	mice.	Abnormal	be-
havior in mouse models could be confounded with many environ-
mental	or	intrinsic	factors,	for	example,	drug-	induced	hyperactivity	
(Silverman,	 Babineau,	Oliver,	 Karras,	 &	 Crawley,	 2013).	 Because	
baclofen treatment unexpectedly led to a worsening of the social 
behavior phenotype in Fmr1 KO mice in the automated tube test 
and an induced phenotype in WT littermates in both behavioral 
tests,	we	analyzed	 the	 locomotor	activity	which	 is	automatically	
recorded by the software during the three- chamber sociability 
test. The mean distance travelled during the sociability phase is 
depicted	 in	 Figure	2e.	 Both	 Fmr1 KO mice and WT littermates 
treated with 1 mg/ml baclofen showed a significantly increased 
locomotor activity compared to littermates receiving aspartame 
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water.	The	 same	effect	was	observed	during	 the	 acclimatization	
phase (data not shown).
3.3 | A lower concentration of baclofen (0.25 mg/
ml) shows similar results, without an increase of 
locomotor activity
Because	 an	 increased	 locomotor	 activity	 was	 observed	 in	 mice	
treated	with	1	mg/ml	baclofen,	we	reduced	the	treatment	dose	to	
0.25	mg/ml	 baclofen,	 where	 no	 increased	 locomotor	 activity	 was	
measured and repeated both behavioral tests.
3.3.1 | Automated tube test
Fmr1 KO mice and WT littermates were treated with 0.25 mg/ml 
baclofen or aspartame drinking water. This resulted in a similar ef-
fect	in	the	automated	tube	test,	as	was	seen	for	1	mg/ml:	Fmr1 KO 
mice treated with baclofen win significantly more matches against 
Fmr1 KO mice receiving aspartame water (Figure 3b). WT littermates 
treated with baclofen win most matches against WT littermates re-
ceiving	aspartame	drinking	water	(Figure	3c).	Baclofen	treatment	did	
not affect the phenotype in matches between Fmr1 KO mice receiv-
ing baclofen and WT littermates receiving aspartame (Figure 3a). 
The	experiments	contained	two	groups	of	six	mice	each,	except	for	
the control experiment of WT littermates receiving aspartame drink-
ing	water	versus	WT	littermates	receiving	baclofen	drinking	water,	
which contained four mice per group.
3.3.2 | Three- chamber sociability test
Figure	3d	 depicts	 the	 time	 sniffing	 for	 all	 four	 groups.	 All	 mice	
sniffed the stranger mouse significantly more than the empty cage. 
Fmr1 KO mice receiving aspartame drinking water sniff the stran-
ger mouse more than WT littermates receiving aspartame drinking 
water. WT mice treated with baclofen showed increased time sniff-
ing the stranger mouse compared to WT mice receiving aspartame 
water,	resulting	in	an	induced	phenotype	in	WT	mice.	There	was	no	
difference in the time spent sniffing the stranger between Fmr1 KO 
mice receiving aspartame drinking water or baclofen drinking water. 
For	each	group	and	genotype,	10	animals	were	used.
3.3.3 | Locomotor activity is not increased
The locomotor activity of Fmr1 KO mice and WT littermates was 
not increased in mice treated with 0.25 mg/ml baclofen compared 
with mice treated with aspartame drinking water during the sociabil-
ity	phase	(Figure	3e).	However,	in	mice	treated	with	0.25	mg/ml	ba-
clofen,	a	small	but	significant	difference	between	Fmr1 KO mice and 
WT	littermates	was	measured	during	the	sociability	phase,	showing	
higher locomotor activity in Fmr1 KO mice than WT littermates.
4  | DISCUSSION
Fragile	X	syndrome	is	often	characterized	by	social	behavior	deficits	
and autism spectrum features that can significantly impair the pa-
tient’s	social	and	adaptive	abilities.	The	main	goal	of	our	study	was	
to	test	whether	we	can	correct	abnormal	social	behavior	in	the	FXS	
mouse	model,	using	baclofen,	a	GABAB	agonist.	As	FXS	is	a	lifelong	
disease,	and	drug	treatment	is	not	expected	to	permanently	reverse	
the	features,	probably	any	drug	treatment	would	need	to	be	chronic.	
For	that	reason,	we	investigated	chronic	baclofen	treatment,	instead	
of	the	often	used	acute	treatment.	To	measure	its	efficacy,	we	used	
two social behavioral paradigms: the automated tube test and the 
three- chamber sociability test. Our results show no improvement in 
the	FXS	phenotype	after	chronic	baclofen	treatment	in	both	social	
behavioral	tests.	As	a	matter	of	fact,	baclofen	seems	to	increase	the	
dominant phenotype of Fmr1 KO mice in the automated tube test 
and even induce aberrant behavior in WT littermates in both behav-
ioral tests. We observed this worsening of the phenotype with two 
doses	of	baclofen.	The	highest	dose,	1	mg/ml,	was	based	on	phar-
macokinetic studies comparing acute intraperitoneal and chronic 
oral administration of the R- baclofen- specific arbaclofen in Fmr1 KO 
mice	(Henderson	et	al.,	2012).	Acute	arbaclofen	administration	cor-
rected several phenotypes. The only data on chronic treatment that 
was described in this paper regarded a corrected spine phenotype 
F IGURE  3 The effect of 0.25 mg/ml baclofen treatment on the behavior of Fmr1 KO mice and WT littermates in the automated tube 
test	and	the	three-	chamber	sociability	test.	(a–c)	Results	of	the	automated	tube	test	expressed	in	percentage	of	matches	won.	(a)	Fmr1 
KO	mice	treated	with	0.25	mg/ml	baclofen	win	most	matches	against	WT	littermates	receiving	aspartame	drinking	water	(binomial	test,	
70%–90%,	p	=	.000,	n = 6 per group). (b) Fmr1 KO mice treated with 0.25 mg/ml baclofen water win most matches from Fmr1 KO mice 
receiving	aspartame	water,	winning	75%	of	the	matches	on	day	1,	which	increases	to	100%	on	day	4	(p = .002 on day 1 to p = .000 on 
day	4,	n = 6 per group). (c) WT littermates treated with 0.25 mg/ml baclofen win most matches from WT littermates receiving aspartame 
water,	winning	80%–100%	of	matches	(p = .01 on day 1 to p	=	.000	on	day	4,	n	=	4	per	group).	(d)	Three-	chamber	sociability	test.	Sociability	
behavior,	expressed	as	average	time	spent	sniffing	the	stranger	mouse,	compared	to	the	time	spent	sniffing	the	empty	cage.	WT	aspartame	
n	=	10,	Fmr1 KO aspartame n	=	10,	WT	baclofen	n	=	10,	Fmr1 KO baclofen n	=	10.	All	groups	sniff	the	stranger	mouse	more	than	the	empty	
cage	(two-	way	RM	ANOVA	with	within-	subject	factor	side	of	stranger,	p = .000). Fmr1 KO mice receiving aspartame water sniff the stranger 
mouse	significantly	more	than	WT	littermates	receiving	aspartame	water	(two-	way	RM	ANOVA,	p	=	.004).	WT	littermates	receiving	baclofen	
water	sniff	the	stranger	mouse	more	than	WT	littermates	receiving	aspartame	water	(two-	way	RM	ANOVA,	p	=	.011),	making	baclofen-	
treated WT mice comparable to Fmr1 KO mice receiving aspartame or Fmr1	KO	mice	receiving	baclofen.	Data	are	expressed	as	mean	±	SE.	
(e)	Locomotor	activity	during	sociability	phase	of	the	three-	chamber	sociability	test.	The	locomotor	activity	does	not	differ	between	
treatments. Fmr1 KO mice receiving baclofen have increased locomotor activity compared to WT littermates receiving baclofen (two- sided 
independent- samples t-	test,	p	=	.000).	Data	presented	as	mean	±	SE.	p-	Values:	^<.05,	*<.01,	**<.001
     |  7 of 12ZEIDLER Et aL.
after 12 days of 0.5 mg/ml arbaclofen in drinking water (Henderson 
et	al.,	 2012).	 Due	 to	 availability	 issues,	 we	 used	 baclofen,	 instead	
of	arbaclofen,	but	corrected	for	the	presence	of	the	less	potent	S-	
baclofen	in	baclofen,	by	doubling	the	dose	to	1	mg/ml.	We	treated	
our	mice	 for	more	 than	 7	weeks.	 In	 contrast	 to	 their	 findings	 for	
acute	 treatment,	 we	 observed	 increased	 locomotor	 activity	 after	
chronic baclofen treatment. This might possibly reflect drug- induced 
hyperactivity.	This	finding	led	us	to	hypothesize	that	the	worsening	
of the social behavior phenotype in the behavioral tests might have 
been confounded with this drug- induced hyperactivity. It is known 
from the literature that drug- induced hyperactivity can influence 
social	 behavior,	 for	 example,	 in	 the	BTBR	mouse	model	 of	 autism	
(Silverman	et	al.,	2013).	For	that	reason,	we	repeated	the	behavio-
ral	 experiments	with	 a	 lower	dose	of	0.25	mg/ml	baclofen,	where	
locomotor	activity	was	not	increased.	However,	still	a	worsening	of	
the social behavioral phenotype and a deleterious effect on WT lit-
termates	were	observed,	independent	of	the	locomotor	activity.	Of	
course,	we	 cannot	exclude	 that	 a	dose	of	0.25	mg/ml	 is	 too	 small	
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for	behavior	improvement.	Instead,	we	observe	a	robust	worsening	
of	the	behavioral	phenotype	also	for	this	dose,	implying	a	possible	
drawback of the use of baclofen.
Hyperactivity	 is	 an	 important	 hallmark	 of	 FXS	 in	 patients.	
Increased locomotor activity in the open- field test has been de-
scribed for Fmr1	KO	mice	(Ding,	Sethna,	&	Wang,	2014;	Mineur	
et	al.,	2002;	Pietropaolo	et	al.,	2011;	Qin	et	al.,	2015;	Sørensen	
et	al.,	 2015;	 Spencer,	 Alekseyenko,	 Serysheva,	 Yuva-	Paylor,	
&	Paylor,	 2005;	 Yuskaitis	 et	al.,	 2010).	When	 analyzing	 the	 lo-
comotor	 activity	 of	 the	 three-	chamber	 sociability	 test,	 we	 did	
not observe an increased locomotor activity in untreated Fmr1 
KO	mice	 compared	with	 their	WT	 littermates.	However,	when	
treated	with	0.25	mg/ml	baclofen,	we	observed	a	small	but	sig-
nificant hyperactive phenotype in the Fmr1	KO	mice,	compared	
with their WT littermates. We did not see this phenotype in 
untreated mice or mice treated with 1 mg/ml baclofen. In the 
literature,	various	groups	 report	different	 findings	 for	 locomo-
tor activity in the three- chamber sociability test. Some papers 
report no differences between Fmr1 KO mice and WT litter-
mates	(Gantois	et	al.,	2013;	Qin	et	al.,	2015),	while	others	show	
increased locomotor activity in Fmr1	KO	mice	 (Sørensen	et	al.,	
2015). The three- chamber sociability test is obviously not val-
idated	 as	 an	open-	field	 test,	 and	 it	 is	 not	 investigated	 to	what	
extent	this	locomotor	activity	is	dependent	on	anxiety,	hyperac-
tivity,	 and	other	 behavioral	 characteristics.	 The	phenotype	we	
observed	 in	0.25	mg/ml,	but	not	 in	1	mg/ml,	could	account	 for	
increased anxiety or hyperactivity in Fmr1	 KO	mice,	 provoked	
by baclofen treatment in a dose that does not sedate the animals 
as a side effect. It is also possible that a higher dose of baclofen 
influences both WT and Fmr1	KO	mice,	resulting	in	a	ceiling	ef-
fect	without	further	increasing	the	locomotor	activity,	while	the	
lower dose slightly affects Fmr1	KO	mice,	without	affecting	WT	
littermates.
Both	baclofen	and	arbaclofen	have	been	tested	in	Fmr1 KO mice 
and	have	been	 shown	 to	 reduce	FXS-	related	phenotypes,	 such	as	
audiogenic	 seizures,	 abnormal	 spine	morphology,	 synaptic	 protein	
synthesis,	 AMPA	 receptor	 internalization,	 repetitive	 behavior,	 and	
hyperactivity	(Henderson	et	al.,	2012;	Pacey	et	al.,	2009;	Qin	et	al.,	
2015;	Sinclair	et	al.,	2017).	Our	results	are	in	a	striking	contrast	with	
these previously reported papers. This difference could be due 
to our use of chronic treatment. The only study that used chronic 
arbaclofen	 treatment,	 although	 administered	 only	 for	 2	weeks	 in	
drinking	 water,	 did	 not	 assess	 behavior	 but	 only	 spine	 morphol-
ogy	 (Henderson	 et	al.,	 2012).	 This	 study	 and	 other	 studies	 have	
shown a reduction of hyperactivity with acute arbaclofen treatment 
(Henderson	 et	al.,	 2012;	 Sinclair	 et	al.,	 2017).	 Another	 difference	
with some of the studies is our use of racemic baclofen instead of R- 
baclofen	or	arbaclofen	(Sanchez-	Ponce	et	al.,	2012).	Unfortunately,	
it	is	difficult	to	assess	the	optimal	dose,	as	there	is	no	relevant	func-
tional biomarker or endophenotype to screen for desirable levels 
of	baclofen	in	the	brain.	Furthermore,	our	results	are	limited	to	the	
social	behavioral	phenotype,	 in	which	the	relevance	of	the	GABAB 
system is unknown.
In	addition	to	FXS,	the	GABAB pathway has also been implicated 
in	several	other	neurodevelopmental	disorders,	including	Rett	syn-
drome,	Down	syndrome,	and	autism	(Deidda,	Bozarth,	&	Cancedda,	
2014).	 The	 effects	 of	 R-	baclofen	 and	 arbaclofen	 have	 also	 been	
studied in mouse models for autism. R- baclofen has been shown to 
reverse social deficits and repetitive behavior in two autism mouse 
models	 (Silverman	 et	al.,	 2015).	 In	 addition,	 arbaclofen	 has	 been	
evaluated	for	patients	with	ASD.	As	was	the	case	in	the	FXS	clinical	
trial,	the	larger	phase	2	randomized	placebo-	controlled	clinical	trial	
with	150	participants	with	ASD	showed	no	improvement	in	the	pri-
mary	outcome	measure.	However,	it	did	demonstrate	improvement	
of	some	specific	outcome	measures	in	post	hoc	analyses	(Erickson	
et	al.,	2014;	Veenstra-	VanderWeele	et	al.,	2017).	 It	 is	currently	not	
known why the promising results in preclinical studies could not be 
replicated	in	patients	with	FXS	or	ASD.	Our	results	do	not	support	
efficacy	 of	 chronic	 baclofen	 treatment	 either,	 possibly	 revealing	
drawbacks of baclofen treatment that might be related to the lack of 
efficacy observed in patients.
In	this	study,	we	used	two	social	behavioral	 tests	 linked	to	au-
tism	and	aberrant	social	behavior	in	mice,	one	of	the	core	features	
of	FXS.	Both	tests	have	been	shown	to	be	useful	in	detecting	effi-
cacy	of	 targeted	 treatment,	 indicating	 their	potential	 in	preclinical	
screening for therapy. The three- chamber sociability test is a mod-
ified	 test	 from	Nadler	 et	al.	 (2004),	Naert	 et	al.	 (2011),	 developed	
to measure social interaction and interest for an unfamiliar mouse 
compared	 to	 an	 object	 (empty	 cage),	 in	 neuropsychiatric	 diseases	
like	ASD.	Gantois	et	al.	 (2013)	showed	a	phenotype	similar	to	ours	
in the three- chamber sociability test: increased sociability in Fmr1 
KO	mice,	 compared	with	WT	 littermates.	 The	 time	 spent	 sniffing	
the	stranger	mouse	is	the	most	important	measure	for	sociability,	in-
volving	direct	and	active	social	approach	and	interaction	(Moy	et	al.,	
2009;	Nadler	et	al.,	2004).	The	 time	 in	chamber	 is	correlated	with	
the time spent sniffing and could be used as an indirect measure-
ment	of	social	interaction	(Gantois	et	al.,	2013;	Nadler	et	al.,	2004;	
Yang,	 Silverman,	 &	 Crawley,	 2011).	 In	 our	 experiments,	 the	 time	
spent	in	the	stranger	chamber	only	approached	significance,	indicat-
ing that sniffing time is probably a more reliable measurement of so-
ciability in Fmr1 KO mice in our setup. Recent publications have also 
demonstrated enhanced sociability in Fmr1	KO	mice,	expressed	as	
time	sniffing	the	stranger	mouse	(Gantois	et	al.,	2013;	Spencer	et	al.,	
2005,	2011;	Thomas	et	al.,	2011)	as	well	as	time	spent	in	the	stranger	
chamber	(Gantois	et	al.,	2013;	McNaughton	et	al.,	2008;	Pietropaolo	
et	al.,	2011).	However,	other	studies	have	demonstrated	decreased	
sociability in Fmr1	KO	mice,	which	seems	more	in	line	with	the	clas-
sic	ASD	features	(Liu	&	Smith,	2009;	Moy	et	al.,	2009;	Sinclair	et	al.,	
2017).	The	differences	between	 these	 studies	 could	be	 related	 to	
differences in genetic background and experimental setup. We mod-
ified	the	three-	chamber	sociability	test	from	Gantois	et	al.	(2013),	by	
recording	only	the	first	five	minutes	of	the	sociability	phase,	as	most	
of the social approach takes place in this time interval and at that 
time,	the	Fmr1 KO phenotype has been shown to be the most obvi-
ous	(Gantois	et	al.,	2013;	Nadler	et	al.,	2004).	Also,	we	only	used	the	
sociability	part,	as	that	has	been	described	to	be	the	most	sensitive	
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and	 relevant	 to	autism-	like	 symptoms	 (Yang	et	al.,	2011).	The	 sec-
ond	part,	preference	for	social	novelty,	is	more	relevant	to	test	social	
recognition	and	memory	(Yang	et	al.,	2011)	and	is	a	less	consistent	
phenotype	(Moy	et	al.,	2007,	2009;	Pietropaolo	et	al.,	2011).
Our	 second	behavioral	 test,	 the	 automated	 tube	 test,	 is	modi-
fied	from	the	paradigm	developed	by	Lindzey	et	al.	(1961)	to	test	the	
effect of different genetic backgrounds on social dominance. Fmr1 
KO	mice	display	a	robust	dominant	phenotype	over	WT	littermates,	
which can be partially reversed by genetic or pharmacological re-
duction	 of	 the	mGluR5	 activity	 (de	 Esch	 et	al.,	 2015).	 In	 addition,	
targeting	the	GABAa	receptor	using	bumetanide	has	shown	a	ben-
eficial	effect	 in	 the	 tube	 test	as	well	 (Zeidler,	de	Boer,	Hukema,	&	
Willemsen,	 2017).	 Also,	 for	 the	 tube	 test,	 conflicting	 results	 have	
been	 described	 by	 different	 groups	 (Goebel-	Goody	 et	al.,	 2012;	
Spencer	et	al.,	2005),	possibly	dependent	on	differences	in	genetic	
background,	experimental	setup,	and	especially	the	training	protocol	
and	housing	conditions	(de	Esch	et	al.,	2015).	In	both	the	automated	
tube	test	and	the	three-	chamber	sociability	test,	the	FXS	phenotype	
might	be	explained	by	an	enhanced	sociability,	disinhibition	in	social	
behavior,	increased	anxiety,	or	a	combination	of	those.	This	fits	the	
observation	that	FXS	patients	often	do	seek	social	contact	and	are	
more	empathetic	and	disinhibited,	unlike	the	social	withdrawal	often	
seen	in	idiopathic	ASD	(Hall,	Lightbody,	Hirt,	Rezvani,	&	Reiss,	2010;	
Steinhausen	et	al.,	2002;	Tranfaglia,	2011).
As	baclofen	 is	a	GABAB	agonist,	we	expected	sedation	to	be	a	
major	 side	 effect;	 hence,	 we	were	 surprised	 to	 find	 an	 increased	
locomotor activity in mice treated with baclofen. Increased lo-
comotor activity could be related to different behaviors in mice 
such	 as	 hyperactivity	 and	 anxiety	 (Kazdoba,	 Leach,	 Silverman,	 &	
Crawley,	2014)	and	might	be	a	major	confounder	on	any	measure-
ment	of	social	deficits	(Silverman	et	al.,	2013).	Thus,	it	is	important	
to address the cause of this paradoxical effect of baclofen. Similar 
paradoxical effects caused by baclofen have been described ear-
lier	 in	patients	with	psychiatric	diseases	or	spasticity,	as	well	as	 in	
mice (outbred CFW and ICR mouse). Symptoms of elevated mood 
disorders	 were	 observed,	 such	 as	 agitation,	 insomnia,	 mania,	 dis-
inhibition,	 aggression,	 or	 seizures	 (Dugladze	 et	al.,	 2013;	Geoffroy	
et	al.,	2014;	Takahashi	et	al.,	2012).	Genetic	background	and	path-
way characteristics probably play a role in response to baclofen be-
cause	variations	in	the	GABAergic	pathway	functioning	in	different	
brain regions can ultimately lead to an undesired combined effect. 
For	other	GABAergic	drugs	like	benzodiazepines,	it	has	been	previ-
ously	hypothesized	that	variation	 in	pathway	characteristics	 in	the	
patient’s	brain	 leads	 to	differences	 in	 the	drug	 response	 (Bruining	
et	al.,	2015;	Marrosu,	Marrosu,	Rachel,	&	Biggio,	1987;	Nardou	et	al.,	
2011).	 Benzodiazepines	 are	 known	 to	 often	 cause	 paradoxical	 ef-
fects	in	patients	with	specific	neurodevelopmental	disorders,	espe-
cially	 autism,	 where	 the	 GABAergic	 pathway	 has	 been	 implicated	
(Bruining	et	al.,	2015;	Mancuso,	Tanzi,	&	Gabay,	2004).	In	addition,	
data regarding tolerance induction after chronic administration of 
baclofen	have	been	reported,	although	it	seems	that	certain	cellular	
targets of baclofen are more prone to this tolerance induction than 
others	(Lehmann,	Mattsson,	Edlund,	Johansson,	&	Ekstrand,	2003).	
The	precise	mechanism	of	tolerance	induction	is	not	known,	as	only	
few studies have focused on chronic systemic baclofen treatment 
and results in the literature are conflicting. One proposed mecha-
nism	is	downregulation	of	the	GABAB receptor- binding sites or phos-
phorylation	of	downstream	signaling	regulators	(Keegan	et	al.,	2015;	
Lehmann	et	al.,	2003;	Pacey,	Tharmalingam,	&	Hampson,	2011).	 In	
addition,	evidence	has	been	published	on	cross	talk	between	GABAB 
receptor	and	mGluR5	receptor	after	chronic	treatment	(Pacey	et	al.,	
2011).	Notably,	treating	Fmr1 KO mice acutely with arbaclofen cor-
rects	mGluR5-	dependent	phenotypes	such	as	AMPA	receptor	inter-
nalization	 and	 protein	 synthesis,	 underlining	 the	 interdependence	
of	 both	 pathways	 (Henderson	 et	al.,	 2012).	 Besides	 the	 above-	
mentioned	variations,	also	unstable	R-	baclofen	concentrations	due	
to the short half- life of the drug are known to contribute to a par-
adoxical	effect	(Lal	et	al.,	2009).	Because	we	treated	the	mice	ad	li-
bitum	with	baclofen	drinking	water,	we	cannot	exclude	fluctuations	
in	the	blood	concentrations.	Nevertheless,	without	quantifying	this	
behavior,	 mice	 treated	 with	 baclofen	 in	 both	 concentrations	 did	
seem	to	be	more	agitated	or	“jumpy.”	However,	no	aggressive	behav-
ior	was	observed.	With	the	lower	concentration	of	baclofen,	no	in-
creased	locomotor	activity	was	measured,	but	this	does	not	exclude	
other	elevated	mood	disorder	effects	on	the	mice.	Probably,	aggres-
sion,	anxiety,	mania,	or	any	other	behavioral	changes,	however	sub-
tle,	could	have	confounded	the	social	behavior	of	the	mice.	We	do	
not know whether our results are due to previously published par-
adoxical effects of baclofen and whether they are relevant for pa-
tients	with	FXS	or	other	neurodevelopmental	disorders.	If	they	are,	
they predict highly undesirable side effects that may not outweigh 
any	possible	 improvement.	Altogether,	 this	 implicates	 that	chronic	
treatment	with	baclofen	might	have	a	different	effect	per	subject,	
depending	 on	 genetic	 variation,	 pathway-	specific	 differences,	 and	
different	effects	of	baclofen	per	brain	region.	Moreover,	the	effect	
could	be	dose	dependent,	dependent	on	duration	of	treatment,	and	
be affected by individual differences in metabolism. It would be in-
teresting to unravel these variations and to be able to predict the 
effect	of	baclofen	in	a	personalized	patient	care	setting.
In	conclusion,	treatment	of	mice	with	baclofen,	a	GABAB	agonist,	
resulted in a worsening of the social phenotype in Fmr1 KO mice 
and even induction of aberrant social behavior in WT littermates. 
This	deleterious	effect	might	be	due	to	hyperactivity,	a	paradoxical	
elevated	mood	effect,	or	agitation.	Our	results	on	chronic	baclofen	
treatment are in sharp contrast with earlier publications on acute 
treatment	of	baclofen	or	arbaclofen	in	FXS	that	have	shown	benefit	
on	multiple	FXS	phenotypes.	As	chronic	baclofen	treatment	wors-
ens	the	FXS	social	behavior	phenotype	of	Fmr1 KO mice and induces 
aberrant social behavior in WT littermates in these social behavioral 
tests,	the	question	can	be	raised	whether	baclofen	is	a	ubiquitously	
effective	treatment	for	FXS	or	might	also	worsen	FXS-	related	fea-
tures in patients. It is unknown whether a similar unexpected effect 
or	paradoxical	effect	could	be	relevant	in	patients	with	FXS,	possibly	
even in part explaining the disappointing results of the arbaclofen 
clinical trials. Future research should address whether this effect 
of	 chronic	 baclofen	 treatment	 is	 consistent	 for	 other	 FXS-	related	
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phenotypes and whether it is specific for certain mice strains or pa-
tient groups. If baclofen would appear to have a beneficial effect in 
a	 subgroup	of	patients	 and	a	deleterious	effect	 in	others,	 the	use	
of	baclofen	would	require	identification	of	predictive	factors	and	a	
personalized	approach.
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